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Summary
Aim.— To assess the feasibility and safety of a hybrid myocardial revascularization strategyrevascularization;
Coronary bypass;
Drug-eluting stent
combining ‘‘exclusive arterial’’ conventional coronary artery bypass grafting (CABG) followed
by early drug-eluting stent (DES) implantation in multivessel coronary artery disease (CAD).
Methods.— Eighteen consecutive patients with multivessel CAD were enrolled prospectively.
Within 48 hours of CABG using left internal mammary artery (IMA) to left anterior descending
(LAD) coronary artery with or without right IMA to non-LAD vessel in an open chest approach,
DESs were implanted systematically in an additional vessel after a clopidogrel 300-mg preloading
Abbreviations: CABG, coronary artery bypass graft; CAD, coronary artery disease; DES, drug-eluting stent; IMA, internal mammary
artery; LAD, left anterior descending; MIDCAB, minimally invasive direct coronary artery bypass; PCI, percutaneous coronary intervention;
RE-MIDCAB, robotically enhanced minimally invasive direct coronary artery bypass; VG, vein graft; RCA, right coronary artery; CPB, car-
diopulmonary bypass; MACE, major adverse cardiac events; MI, myocardial infarction; TVR, target vessel revascularization; CK, creatinine
kinase; ULN, upper limit of normal; TIMI, thrombolysis in myocardial infarction.
∗ Corresponding author. Fax: +33 32 04 6065.
E-mail address: t1modine@yahoo.fr (T. Modine).
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dose. This group was compared with 18 matched patients who underwent standard CABG alone
using left IMA to LAD and at least one additional graft.
Results.— Baseline clinical characteristics were similar in both groups. There were 46 grafts
in the CABG group and 28 in the hybrid group. In the hybrid group, 27.8% of patients were
treated off-pump versus none in the CABG group; a median of 2 (interquartile range: 1—2)
stents was implanted per patient. The hybrid procedure was associated with shorter durations
of cardiopulmonary bypass (77 [67—100] min versus 97 [90—105] min, P = 0.049). Major bleed-
ing rates were higher in the CABG group, but the difference was not statistically signiﬁcant
(44.4% versus 11.1%, P = 0.06). Re-intervention for bleeding was not needed in either group.
One (5.6%) myocardial infarction occurred in hospital in each group following CABG. At 1 year,
the cumulative rates of major adverse cardiac events (death, myocardial infarction, target ves-
sel revascularization) were similar (11.2% in hybrid group versus 5.6% in CABG group, P = 0.99).
One death occurred in the CABG group and one target vessel revascularization in the hybrid
group.
Conclusion.— A hybrid revascularization strategy, combining conventional CABG with exclusive
arterial conduits followed by early DES implantation, is feasible. One-year event rates compare
favourably to those with traditional CABG alone.
© 2010 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Revascularization
hybride ;
Pontage coronaire ;
Stent actif
Résumé
Objectifs.— Évaluer la faisabilité et la sécurité d’une stratégie de revascularisation
myocardique hybride combinant pontage coronaire (PC) « exclusivement artériel », suivi de
l’implantation précoce d’un ou de plusieurs stents actifs (SA) chez des patients présentant
une atteinte multitronculaire.
Méthodes.— Dix-huit patients présentant une maladie coronaire multitronculaire ont été inclus
de manière prospective. Dans les 48 heures suivant la réalisation d’un PC à thorax ouvert (artère
mammaire interne (AMI) gauche greffée sur l’artère interventriculaire antérieure [IVA]±AMI
droite sur un autre vaisseau que l’IVA), au moins un SA était systématiquement implanté sur
une des lésions non pontées après une dose de charge de 300mg de clopidogrel. Ce groupe était
comparé à 18 patients appariés ayant bénéﬁcié uniquement d’un PC traditionnel associant AMI
gauche greffée sur l’IVA et au moins une veine durant la même période.
Résultats.— Les caractéristiques cliniques de base étaient similaires dans les deux groupes. Il y
avait 46 greffons dans le groupe PC seul et 28 greffons dans le groupe hybride, avec une médiane
de 2 [25—75e percentile : 1—2] stents implantés par patient. Dans le groupe hybride, 27,8 % des
patients étaient traités à cœur battant, alors qu’aucun patient ne l’était dans le groupe PC seul.
Ainsi pour les patients opérés sous circulation extracorporelle (CEC), la procédure hybride était
associée à des durées plus courtes de CEC (77 [67—100] minutes versus 97 [90—105] minutes ;
p = 0,049). Le taux de saignement majeur avait tendance à être plus élevé dans le groupe PC
seul (44,4 % versus 11,1 % ; p = 0,06). Il n’y avait pas de réintervention pour cause de saignements
dans les deux groupes. Un (5,6 %) infarctus du myocarde est survenu en milieu intrahospitalier
dans le groupe PC seul. Aucune complication de l’angioplastie n’était constatée dans le groupe
hybride. À un an, le taux cumulé d’évènement cardiaque indésirable déﬁni comme l’association
de décès, infarctus du myocarde et revascularisation du vaisseau cible était similaire dans les
deux groupes (11,2 % dans le groupe hybride versus 5,6 % dans le groupe PC seul ; p = 0,99). Un
décès était constaté dans le groupe PC seule et une revascularisation du vaisseau cible dans le
groupe hybride.
Conclusion.— Une stratégie de revascularisation hybride combinant PC exclusivement artériel
suivi de l’implantation précoce de SA apparaît comme faisable et semble être, à un an, au
moins aussi sûre et efﬁcace qu’une revascularisation par PC seul.
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Introduction
Coronary artery bypass graft (CABG) surgery, involving graft-
ing of the left internal mammary artery (IMA) to the left
anterior descending (LAD) artery with additional vein graft
(VG), remains the standard technique for treatment of mul-
tivessel coronary artery disease (CAD) [1—3]. The left IMA
r
w
h
ss droits réservés.
rafted to the LAD provides the best long-term patency and
urvival beneﬁt over percutaneous coronary intervention
PCI) for treating LAD stenosis [4,5]. As recent studies have
eported a high rate of VG occlusion, which can reach >25%
ithin 12—18 months [6,7], the long-term outcome of VGs
as been questioned. The advent of PCI with drug-eluting
tents (DES) [8] has resulted in a reduction in restenosis
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Table 1 Two-stage hybrid-procedurea studies, comprising coronary artery bypass graft followed by percutaneous coro-
nary intervention.
Lead author (year) nb Surgical
procedure
Delay between
CABG and PCI
Delay between CABG
and PCI (range)
DES use
Lloyd et al. (1999) [32] 14 MIDCAB NR From 1—3 days No
Wittwer et al. (2000) [33] 35 MIDCAB 7 days (median) NR No
Stahl et al. (2002) [8] 35 RE-MIDCAB 16 days (mean) From 18 hours to 3
months
No
Riess et al. (2002) [34] 53 MIDCAB 5 days (median) From 2—7 days No
Davidavicius et al. (2005) [35] 6 RE-MIDCAB NR In-hospital to 160
days
Yes, 1
patient only
Katz et al. (2006) [36] 12 RE-MIDCAB 16 days (mean) From 2—60 days Yes, 63% of
patients
Holzhey et al. (2008) [37] 59 RE-MIDCAB or
MIDCAB
NR From 2—45 days Yes
Gao et al. (2009) [38] 10 RE-MIDCAB NR From 4—5 days Yes, 20% of
patients
CABG: coronary artery bypass graft; DES: drug-eluting stent; MIDCAB: minimally invasive direct coronary artery bypass; NR: not reported;
PCI: percutaneous coronary intervention; RE-MIDCAB: robotically enhanced minimally invasive direct coronary artery bypass.
a In separate rooms.
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Pb Number of patients who underwent the two-stage hybrid proce
ates and the need for repeat revascularization versus PCI
ith bare-metal stents, with a 12-month restenosis rate
aking this revascularization technique an attractive option
ompared with VGs [9—12]. Both CABG and PCI have their
imitations and advantages, but rather than viewing them as
utually exclusive, there may be a role for their combined
se in speciﬁc patient populations.
Recent studies have reported the feasibility and safety of
simultaneous hybrid coronary revascularization technique
ombining CABG with left IMA to LAD and DES implantation
or treating multivessel CAD [13—17], but owing to logisti-
al and practical concerns, few teams have been able to
rovide it. Given these considerations, a two-stage revas-
ularization process combining CABG and DES implantation
ould offer a more realistic alternative. Several teams have
eported the feasibility of performing CABG followed by
CI (Table 1). However, these studies used either a min-
mally invasive direct coronary artery bypass (MIDCAB) or
obotically enhanced-MIDCAB (RE-MIDCAB). Besides sizeable
ogistical issues making these techniques available for only a
estricted number of teams, this minimally invasive surgery
s limited mostly to revascularization of the LAD territory,
s the circumﬂex and right coronary arteries (RCAs) are less
ccessible. Using a hybrid approach involves revasculariza-
ion of all of the other vessels by PCI, but even in the ‘‘DES
ra’’, PCI remains limited to suitable anatomical lesions.
The use of the right IMA in addition to left IMA grafting
ith a conventional open chest approach has been shown
o provide long-term beneﬁts when compared with revas-
ularization using a single left IMA and VG [18—20]. Thus
hybrid revascularization combining ‘‘exclusive arterial’’
ABG with DES implantation — the most successful applica-
ions of surgical and percutaneous techniques in patients
ith multivessel CAD— appears very attractive. Besides
t
t
s
w
cvoiding non-arterial grafts, this hybrid approach could be
elpful in cases of poor or non-harvestable grafts as well as
or reducing the duration of surgery.
Here, we report the feasibility, safety and outcomes of
hybrid revascularization strategy combining conventional
ABG with exclusive arterial conduits (left IMA to LAD with
r without right IMA to non-LAD vessel) with a conventional
pen chest approach, followed by early DES implantation, in
atients with multivessel CAD. This revascularization strat-
gy was compared with a conventional approach using CAGB
lone.
ethods
tudy population
etween October 2006 and January 2008, 18 patients with
ultivessel CAD were enrolled prospectively to undergo
yocardial revascularization. The hybrid strategy associ-
ted CABG with exclusive arterial conduits (left IMA to LAD
ith or without right IMA to non-LAD vessel) followed, within
8 hours, by DES implantation in an additional vessel.
Inclusion criteria for hybrid revascularization were the
resence of multivessel CAD, a >70% LAD obstruction judged
uitable for surgery, and the presence of a non-LAD lesion(s)
uitable for either right IMA graft and PCI, or PCI only.
atients not suitable for treatment with dual antiplatelet
herapy (aspirin plus clopidogrel) for at least 1 year, those
aking an oral anticoagulant, and patients scheduled for
urgery within 1 year after PCI were excluded. All cases
ere validated by both the surgeon and the interventional
ardiologist.
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Using a prospective case-controlled study design, a paral-
lel control group of 18 patients who underwent conventional
CABG alone (left IMA to LAD and additional grafts for non-
LAD vessels: VG for double bypass and VG plus right IMA for
triple bypass) during the same period of time was matched,
according to sex, age, diabetes, clinical presentation and
number of treated vessels.
All patients provided informed consent to be enrolled in
the study and to anonymous data analysis. The study was
approved by and registered with the local ethics committee.
Surgical procedure
Pharmacological management
All patients were given oral antiplatelet therapy with aspirin
160mg/day before and after CABG. Patients taking clopi-
dogrel stopped this treatment 5 days before the CABG
procedure. Preoperative statin therapy was given system-
atically. Systemic treatment with unfractionated heparin
was given after internal mammary harvesting: 300U/kg for
on-pump CABG surgery and 100U/kg for off-pump CABG.
Heparin was antagonized with protamine sulphate at a ratio
of 1:1 upon completion of distal and proximal coronary anas-
tomosis or weaning of the cardiopulmonary bypass (CPB) in
both groups.
Surgery
Median sternotomy was performed in all patients. The left
IMA was harvested, together with additional graft material
(right IMA and/or VG). The decision to use either on-pump
or off-pump CABG was left to the discretion of the surgeon.
On-pump coronary artery bypass graft surgery
Intermittent cold blood hyperkaliemic cardioplegia and
moderate hypothermia (33 ◦C) were used in all CABG
patients. During CPB, the mean arterial pressure was
allowed to vary between 60 and 90mmHg. Tight glycaemic
control (<1.5 g) was observed until discharge.
Off-pump coronary artery bypass graft surgery
Stabilization of the beating heart was established with the
Octopus III® (Medtronic Inc., Minneapolis, MN). Heart dis-
placement into varied grafting positions was aided by the use
of deep pericardial retraction sutures facilitating exposure
of lateral and posterior walls. The Trendelenburg’s position
was used and the table tilted when necessary. No apical
suction devices were used to assist immobilization. Intra-
coronary shunts were not used in this study.
Percutaneous coronary intervention
procedure for hybrid revascularization
Coronary stenting was performed using conventional tech-
niques, within 48 hours of CABG. The interventional strategy
was left to the discretion of the operator. In all cases, a
femoral approach was employed. All patients underwent
postoperative angiography to demonstrate patency of the
grafts at the time of the PCI. Intraprocedural anticoag-
ulation was ensured using unfractionated heparin with a
bolus of 40—50U/kg. Glycoprotein IIb/IIIa inhibitors were
not used. All patients received aspirin 160mg/day before
the procedure and continued this regimen indeﬁnitely. All
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atients received a clopidogrel loading dose of 300mg,
hours before PCI, followed by a maintenance dose of
5mg/day after PCI for at least 1 year. The sheath was
emoved at the end of the procedure using manual compres-
ion or an arterial closure device.
ollow-up and deﬁnition endpoints
ll patients attended routine clinical follow-up and were
ontacted by a nurse to assess long-term clinical outcome.
he primary endpoint was the 1-year rate of major adverse
ardiac events (MACE) deﬁned as the composite of death,
yocardial infarction (MI) and target vessel revasculariza-
ion (TVR). Death was deﬁned as all-cause mortality. MI was
eﬁned as creatinine kinase (CK) ≥5 times the upper limit
f normal (ULN) within 24 hours after CABG, CK ≥3 times
he ULN within 24 hours after PCI, and thereafter as CK
2 times the ULN and/or ischaemic electrocardiographic
hanges including ST elevation ≥1mm or new Q-waves.
VR was characterized by ischaemia-driven percutaneous
r surgical revascularization of the treated vessel. Deﬁnite
tent thrombosis was considered as deﬁned by the Academic
esearch Consortium [21]. Procedural success was deﬁned
s attainment of both thrombolysis in myocardial infarc-
ion (TIMI) ﬂow grade 3 and a residual stenosis <30%. Major
leeding was deﬁned as the TIMI study group deﬁnition,
.e. a decrease in haematocrit of ≥15% and/or the occur-
ence of intracranial bleeding [22]. CABG-related bleeding
as included in the deﬁnition.
YNTAX score calculation
he SYNTAX score is an angiographic tool that allows clin-
cians to grade the complexity of CAD: the higher the
core, the more complex the disease. The SYNTAX score
or each patient was calculated retrospectively by two
nterventional cardiologists blinded to the group assign-
ent. All coronary lesions with a diameter stenosis of
50% in vessels of ≥1.5mm were scored according to the
YNTAX score algorithm, which has been described else-
here [23] and is available on the SYNTAX score website
www.syntaxscore.com) [24].
tatistical analysis
ontinuous variables are shown as medians (25—75th
ercentiles). Categorical variables are expressed as per-
entages. The Mann-Whitney test was used to compare
ontinuous variables and the Chi2 test or Fisher’s exact test
o compare categorical variables. Statistical signiﬁcance
as assumed at P < 0.05. All analyses were conducted using
PSS 11.0 software (SPSS Inc., Chicago, IL, USA).
esults
atients’ characteristicsatients’ baseline characteristics are shown in Table 2.
here were no differences in the baseline characteristics
f patients in the CABG group and those in the hybrid group.
ixteen (88.9%) patients in both groups had three-vessel
AD.
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Table 2 Patients’ baseline characteristics.
Variable CABG group(n = 18) Hybrid group(n = 18) P
Demographic
Age (years) 60 (53—68) 62 (55—70) 0.36
Female sex 4 (22.2) 4 (22.2) 1.00
Cardiovascular risk factor
Diabetes mellitusa 7 (38.9) 8 (44.5) 0.74
Hypertensionb 14 (77.8) 12 (66.7) 0.71
History of smoking 7 (38.9) 8 (44.4) 0.36
Body mass index (kg/m2) 27 (24—31) 28 (23—31) 0.91
Hypercholesterolaemiac 12 (66.7) 15 (83.3) 0.44
Chronic renal failured 1 (5.6) 0 (0%) 1.00
Cardiovascular history
Stroke 0 (0) 2 (11.1) 0.49
Myocardial infarction 3 (16.7) 5 (27.8) 0.69
CABG 0 (0.0) 0 (0.0) —
Peripheral vascular diseasee 3 (16.7) 5 (27.8) 0.69
Indication for PCI
Stable angina 5 (27.8) 8 (44.4) 0.30
Acute coronary syndrome 13 (72.2) 10 (55.6) 0.30
Left ventricular ejection fraction (%) 60 (55—65) 60 (54—65) 0.84
Three-vessel disease 16 (88.9) 16 (88.9) 1.00
Baseline haemoglobin 13.6 (12.0—15.0) 12.7 (11.8—13.9) 0.17
MI: myocardial infarction; CABG: coronary artery bypass graft; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary
intervention. Data expressed as median (25—75th percentile) or number (%).
a Any history of diabetes mellitus and/or use of hypoglycaemic drugs, and including a new diagnosis made during the index hospitalization
with a fasting glucose level of ≥1.26 g/l on ≥2 separate occasions.
b History of hypertension diagnosed and/or treated with medication or currently being treated with diet and/or medication by a
physician.
c Includes patients with a previously documented diagnosis of hypercholesterolaemia. The patient may be treated with diet or medica-
tion. A new diagnosis can be made during this hospitalization with an elevated total cholesterol >160mg/dl; does not include elevated
triglycerides.
d Deﬁned as clearance creatinine ≤60ml/min calculated using the Cockroft-Gault equation.
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ntervention characteristics
perative and PCI characteristics are given in Table 3 and a
ummary of the grafts in Table 4. Forty-six grafts were done
n the CABG group and 28 in the hybrid group (Table 4).
The SYNTAX score was similar in both groups (P = 0.23).
ll 18 patients in the CABG group and 13 in the hybrid group
nderwent on-pump CABG. In the ﬁve patients treated with
ff-pump CABG, four underwent left IMA to LAD bypass only
nd the ﬁfth had left IMA to LAD and right IMA to diagonal
ranch. In patients with on-pump CABG, the hybrid proce-
ure was associated with shorter CBP time (P = 0.04).
In the hybrid group, angiographic success was achieved in
6.6% of patients; there was one PCI failure because of the
nability to cross the lesion (distal RCA) with a wire. There
ere no PCI complications. Twenty-six of the 29 lesions
ere ‘‘on label’’ according to the French guidelines for DES
ndication [25]. On checking the CABG, one anastomotic
efect was found on a right IMA graft to obtuse marginal
nd one proximal occlusion of a right IMA graft to obtuse
h
s
o
Ocular surgery or non-traumatic amputations.
arginal; both patients were treated medically because
hey are unsuitable for PCI. No defects were found in the
eft IMA graft.
linical outcomes
n-hospital bleeding and vascular complications are reported
n Table 5. All patients in the hybrid group who received
loading dose of clopidogrel after CABG underwent PCI.
lthough not statistically signiﬁcant, the rates of major
leeding and need for transfusion were higher in the CABG
roup than in the hybrid group (respectively, 44.4% versus
1.1%, P = 0.06; 39.3% versus 11.1%, P = 0.23). No patients
equired re-intervention for bleeding or tamponade. The
edian length of hospitalization was similar in the two
roups. Three patients in the CABG group and none in the
ybrid group (P = 0.23) reported a 25% worsening in baseline
erum creatinine at 5 days after discharge from the CABG
perative room.
In-hospital and 1-year outcomes are reported Table 6.
ne in-hospital MI occurred in each group. In the hybrid
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Table 3 Operative and percutaneous coronary intervention characteristics.
Variable (patient-based) CABG group(n = 18) Hybrid group(n = 18) P
SYNTAX score 24.0 (17.7—30.0) 25.2 (22.2—37.9) 0.23
CABG characteristic
Number of arterial grafts per patient 2 (1—2) 2 (1—2) 1.00
Number of VGs per patient 1 (1—1) 0 —
Off-pump CABG 0 (0.0) 5 (27.8) 0.04
CBP time, if applicable, (min) 97 (90—105) 77 (61—100) 0.04
PCI (within 48 hours of CABG)
Dose of unfractionated heparin (U) — 2650 (2400—3000) —
Number of dilated lesions — 2 (1—2) —
Number of DES implanted per patient — 2 (1—2) —
Closure device — 5 (27.8) —
Contrast amount (ml) — 175 (145—245) —
Fluoroscopy time (min) — 10 (7—17)
Dose area product (Gray/cm2) — 72 (41—111) —
Time between discharge from CABG operative room and PCI (hours) — 41 (37—44)
Variable (lesion-based) Hybrid group (n = 29) P
Target coronary vessel
Left main — 2 (6.9) —
LADa — 1 (3.5) —
OM — 9 (31.0) —
RCA — 17 (58.6) —
VG — 0 (0.0) —
Left IMA/right IMA — 0 (0.0) —
Type B2/C lesion (ACC/AHA class) 20 (68.9)
Calciﬁcationb
None — 12 (14.5)
Moderate — 11 (13.5)
Severe — 6 (7.2)
Angiographic success — 28 (96.6) —
PCI complication
No reﬂowing — 0 (0.0) —
Abrupt closure — 0 (0.0)
Dissection — 0 (0.0)
Restenosis lesion — 1 (3.4) —
Lesion length (mm) — 10 (14—19)
Reference vessel diameter (mm) — 2.7 (2.5—3.3)
Stent length (mm) — 12 (12—17) —
Stent diameter (mm) — 2.5 (2.5—3.0) —
Minimal lumen diameter before procedure (mm) — 0.64 (0.43—0.94) —
Minimal lumen diameter after procedure (mm) — 2.90 (2.48—3.06) —
Preprocedural % diameter stenosis — 77 (65—84) —
Post-procedural % diameter stenosis — 1 (0—5) —
ACC/AHA: American College of Cardiology/American Heart Association; CBP: cardiopulmonary bypass; DES: drug-eluting stent; IMA:
internal mammary artery; LAD: left anterior descending; OM: obtuse marginal; RCA: right coronary artery; UFH: unfractionated heparin;
VG: vein graft. Data expressed as median (25—75th percentile) or as number (%).
a One patient had both grafting of the distal LAD and stenting for a proximal lesion.
b Calciﬁcation was identiﬁed as readily apparent radio-opacities within the vascular wall at the site of the lesion and was classiﬁed as
none, moderate (radio-opacities noted only during the cardiac cycle before contrast injection) and severe (radio-opacities noted without
cardiac motion before contrast injection generally compromising the two sides of the arterial lumen).
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Table 4 Summary of grafts.
Variable CABG group Hybrid group
Grafts 46 28
Patients with double bypass 8 8
Left IMA to LAD 8 8
VG to OM or RCA 5OM, 3 RCA DES
Patients with triple bypass 10 10
Left IMA to LAD 10 10
Right IMA to OM, DB or RCA 9 OM, 1 DB 7 OM, 2 DB, 1 RCA
VG to RCA 10 DES
DB: diagonal branch; DES: drug-eluting stent; LAD: left anterior descending artery; IMA: internal mammary artery; OM: obtuse marginal;
RCA: right coronary artery; VG: vein graft. Data expressed as number.
Table 5 In-hospital bleeding and vascular complications.
Variable CABG group(n = 18) Hybrid group(n = 18) P
Bleeding complication
Total postoperative drain output (ml) 1010 (685—1250) 950 (732—154) 0.88
Post-clopidogrel LD drain output (ml) — 185 (60—312) —
Re-intervention for bleeding or tamponade 0 (0.0) 0 (0.0) —
Need of transfusion 6 (39.3) 2 (11.1) 0.23
Intracerebral bleeding 0 (0.0) 0 (0.0) —
Haemoglobin drop (g/dl) 4.2 (2.7—5.9) 2.4 (1.5—4.2) 0.008
Haemoglobin drop ≥5 g/dl 8 (44.4) 2 (11.1) 0.06
Major bleeding 8 (44.4) 2 (11.1) 0.06
Vascular complication 0 (0) 0 (0) —
Median length of hospital stay from CABG (days) 10.5 (10.0—12.5) 10.0 (10.0—11.2) 0.33
25% worsening of baseline serum creatinine 3 (17) 0 (0) 0.23
5 days after surgery
CABG: coronary artery bypass graft; LD: loading dose. Data expressed as median (25—75th percentile) or as number (%).
Table 6 In-hospital and 1-year ischaemic outcomes.
Variable CABG group(n = 18) Hybrid group(n = 18) P
In-hospital event
Death 0 (0.0) 0 (0.0) —
MI 1 (5.6) 1 (5.6) 1.00
TVR 0 (0.0) 0 (0.0) —
MACE (death/MI/TVR) 1 (5.6) 1 (5.6) 1.00
Cumulative 1-year events
Death 1 (5.6) 0 (0) 1.00
MI 1 (5.6) 1 (5.6) 1.00
Death/MI 1 (5.6) 1 (5.6) 1.00
TVR 0 (0.0) 1 (5.6) 1.00
MACE (death/MI/TVR) 1 (5.6) 2 (11.2) 0.99
Stent thrombosis — 0 (0.0) —
Stroke 0 (0.0) 0 (0.0) —
MACE: major adverse cardiac event; MI: myocardial infarction; TVR: target vessel revascularization. Data expressed as n (%).
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group, in-hospital MI was diagnosed with a rise in CK within
24 hours after CABG and was related to a middle RCA suboc-
clusion, which underwent PCI the following day. In-hospital
rates of MACE were the same, and were due to the in-
hospital MIs. At 1 year, there was one (5.6%) death in the
CABG group and one TVR (5.6%) in the hybrid group; the
cumulative rates of MACE were similar (P = 0.99).
Discussion
The main ﬁnding of this study is that hybrid revasculariza-
tion, combining conventional CABG with exclusive arterial
conduits and a conventional open chest approach followed
by early DES implantation, is feasible in patients with multi-
vessel CAD. Moreover, this approach appears as safe and as
effective as that of standard management by CABG alone,
with identical 1-year outcomes.
Starting with CABG and following with PCI offers sev-
eral advantages over the reverse strategy. First, it avoids
bleeding complications, as treatment with clopidogrel plus
aspirin before CABG is associated with higher rates of post-
operative bleeding and morbidity [26—29]. In spite of a
clopidogrel loading dose given within 48 hours of CABG in
all patients in the hybrid group, the rate of bleeding was
not higher than that in the conventional CABG group, and
even tended to be lower. Indeed, although not statistically
signiﬁcant, there was a greater than three fold decrease in
the need for transfusion, and the rate of major bleeding was
higher in the CABG group, as reﬂected by the greater drop in
haemoglobin. This difference may be explained by the more
frequent use of off-pump CABG and the 20% decrease in the
CBP time in the hybrid group, which was probably related to
the reduced number of grafts. However, these results should
be interpreted with caution given the small sample size of
the study.
As shown in Table 1, most studies using less invasive
CABG techniques performed the PCI some time after the
surgery (>48 hours). In the present study, we show that PCI
with a clopidogrel preloading dose can be performed within
48 hours of conventional open chest CABG surgery without
increasing the bleeding risk compared with a more tradi-
tional approach. This revascularization sequence did not
affect the length of hospital stay, which appeared similar
between the hybrid group and the CABG group. Secondly,
by starting the hybrid procedure with CABG allowed the PCI
to be performed in a ‘protected’ environment, especially
with regards to the anterior myocardial wall. This protection
makes PCI suitable even for the left main, which was done in
one patient. Finally, this revascularization strategy allowed
clinicians to check the patency of the graft at the time of
PCI, although the defects identiﬁed at this time could not
be always resolved with PCI. In our cohort, two patients had
defects (one anastomotic defect and one occlusion) on the
right IMA to obtuse marginal, which were treated medically.
Concerns exist regarding the performance of PCI within
48 hours of CABG. The ﬁrst is the risk of coronary ischaemic
events occurring in the inﬂammatory postoperative period.
No cases of stent thrombosis occurred in our small cohort,
in which every patient received a clopidogrel loading dose
before PCI. However, one patient experienced MI after the
CABG, related to a subocclusion of the vessel planned for
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reatment by PCI on the following day. In addition, the rate
f in-hospital MI was similar between the hybrid approach
nd the standard CABG approach. The second concern is
he possibility of a PCI complication or failure resulting in
he need for a second and much higher risk surgical pro-
edure. Nevertheless with improvements in the technique,
he risks of complications relating to PCI and stent failure
ith the need for emergency bypass surgery have become
ery rare [30]; we observed a high angiographic success
ate, around 97%, in our cohort and encountered no PCI
omplications.
Several research teams have reported their experience of
he hybrid approach with DES, using either a simultaneous
equence [13—17] or combining two-stage CABG followed
y PCI using MIDCAB or RE-MIDCAB (Table 1). In the present
tudy, we show that it is safe to perform DES implantation
ust after conventional open chest CABG with a clopidogrel
reloading dose. No difference between the hybrid group
nd the standard CABG group (using VG) was found in terms
f 1-year MACE, and we conﬁrm the good clinical outcome of
ES [9—12], with no cases of clinical restenosis at 1 year. The
VR at 1 year was due to an atherosclerotic plaque rupture
ocated far away from the stent.
Finally, the complexity of the CAD was similar between
he hybrid group and the CABG group, as shown by the
YNTAX scores (25.2 and 24.0, respectively, P = 0.23). In
he SYNTAX study, patients with multivessel CAD and a
YNTAX score ≥23 had a higher rate of major adverse car-
iovascular and cerebrovascular events after PCI than after
ABG [23]. In the randomized SYNTAX study, >80% of the
atients in the CABG group underwent at least one VG [31].
wing to concerns about VG outcome [6,7], it is plausible
hat combining the best of modern revascularization tech-
iques such as exclusive mammary arterial conduit CABG
nd DES implantation could improve clinical outcome, espe-
ially in multivessel CAD patients in whom the SYNTAX score
s >23.
imitations
he main limitation of our study is the small size of the
ohort, which may have resulted in a failure to recognize
inor differences between the hybrid group and the stan-
ard CABG group. Indeed, the hybrid approach has not yet
een widely validated, and thus was difﬁcult to justify
or patients and colleagues. Moreover, PCI was supposed
o be performed within 48 hours after CABG, leading to
roblems with the inclusion of patients towards the end
f the working week. Another limitation is the lack of sys-
ematic angiographic control of graft and stent patency at
-year follow-up, which may also have been too short to
dentify a difference in outcomes. A deﬁnitive comparison
ould, however, require a large, prospective, randomized
rial with long-term follow-up, which is itself a compelling
hallenge. Finally, all patients in the CABG group under-
ent on-pump CABG, which may have been responsible for
he higher morbidity, such as bleeding. However, patients in
his control group represent the usual surgical practice in
ur centre, in which >500 CABG procedures are performed
nnually.
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onclusions
he hybrid procedure, combining open chest CABG with
‘exclusive arterial conduit(s)’’ followed by early DES
mplantation, is feasible, and appears safe and effective
n selected patients with multivessel CAD, with a satisfac-
ory 1-year performance compared with conventional CABG
lone.
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